---
title: " Medical Underwriting: Global Health Brief – Liquid Biopsy"
date: 2018-03-15T18:07:19+0000
author: matt
draft: True
---
Liquid biopsies are noninvasive tests that could potentially lead to early detection of cancer by identifying the genetic material cancerous tumors shed into the bloodstream and other bodily fluids. It is now possible to test  for biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). As these tests gain a foothold in clinical practice, insurance professionals must understand liquid biopsies and the implications for underwriting and product development.

[ Medical Underwriting: Global Health Brief – Liquid Biopsy ]( http://www.rgare.com/knowledge-center/media/articles/global-health-brief-liquid-biopsy )
